Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen

González Vacarezza, Nicolás; Alonso, Isabel; Arroyo, Gustavo; Martínez, Jorge; De Andrés, Fernando; Llerena, Adrián; Estévez Carrizo, Francisco.
Drug Metab. Pers. Ther ; 31(2): 83-90, junio, 2016.
Artículo en Inglés | URUCAN | ID: bcc-5097

Documentos relacionados

  1. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
  2. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis.
  3. Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients.
  4. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
  5. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
  6. Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies.
  7. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis.
  8. Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
  9. High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab.
  10. Incorporating anti-VEGF pathway therapy as a continuum of care in metastatic colorectal cancer.